CVS Health Corp
CVS- Exchange
- NYSE
- Industry
- Retail-Drug Stores and Proprietary Stores
- SEC CIK
- 0000064803
No open-market purchases or sales by CVS Health Corp insiders were filed in the last 90 days; 2,074 institutions reported holding it in 13F filings for Q2 2026, worth $118.9B in total; 3 superinvestors hold it, including Viking Global Investors and Fairfax Financial.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +215 vs. previous quarter
- 2,074
- 13F valueReported value at the end of Q2 2026
- $118.9B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Superinvestors holding CVS, Q2 2026
3 superinvestors report holding CVS Health Corp on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
1.1%
CVS Health Corp's share of the portfolio
- Shares
- 3,663,361
- Value
- $379.0M
| Superinvestor | Weight | Value |
|---|---|---|
| Harris Associates (Oakmark) | <0.1% | $34.7M |
Latest insider trades
Open-market purchases and sales by CVS Health Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 (view filing) | May 19-21 | 2 days | Robbins LarryDirector | SSale | −3.37M | $94.15 | −$317.5M | −41.1%4.82M after | 7 lots |
| May 21, 2026 (view filing) | May 21 | Same day | Robbins LarryDirector | SSale | −378.0K | $93.31 | −$35.3M | –0 after | Derivative |
| May 11, 2026 (view filing) | May 8 | 3 days | Mandadi TilakEVP, Chief Exp & Tech Officer | SSale | −69.6K | $89.58 | −$6.23M | −87.3%10.1K after | |
| Jan 27, 2026 (view filing) | Jan 23, 2025 | 369 daysLate | Nelson Steven HEVP and President, Aetna | PPurchaseCommon Stock (By Trust) | +24 | $53.70 | +$1.29K | New position24 after | |
| Oct 14, 2025 (view filing) | Sep 9-Oct 23, 2024 | 400 daysLate | Capozzi Heidi BEVP and Chief People Officer | PPurchase | +80 | $57.36 | +$4.59K | +1,600.0%85 after | 3 lots |
| Aug 29, 2025 (view filing) | Aug 20 | 9 daysLate | Finucane Anne A.Director | SSale | −7.50K | $71.02 | −$532.6K | −25.3%22.2K after | |
| Jun 9, 2025 (view filing) | Jun 5 | 4 days | Sansone Guy PDirector | PPurchase | +1.57K | $63.70 | +$100.0K | +15.0%12.0K after | |
| May 6, 2025 (view filing) | May 2-6 | 4 days | Robbins LarryDirector | SSale | −3.75M | $67.66 | −$253.7M | −31.4%8.20M after | 6 lots |
| Mar 7, 2025 (view filing) | Mar 5 | 2 days | Clark James DavidSVP, Cont & Chief Acct Officer | SSale | −7.51K | $66.35 | −$498.5K | −47.2%8.39K after | |
| Feb 19, 2025 (view filing) | Feb 18 | 1 day | Mahoney Michael FDirector | PPurchaseCommon Stock (By Trust) | +30.0K | $66.70 | +$2.00M | +320.6%39.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in CVS Health Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 123,223,409 | $12.7B | 0.19% | −2,696,444−2.1% | Reduced |
| Vanguard Capital Management LLC | 83,315,369 | $8.62B | 0.18% | +665,293+0.8% | Added |
| Capital World Investors | 74,951,955 | $7.75B | 0.92% | −2,296,687−3.0% | Reduced |
| State Street Corp | 60,283,408 | $6.24B | 0.18% | +961,227+1.6% | Added |
| Dodge & Cox | 50,012,765 | $5.17B | 2.71% | −1,767,351−3.4% | Reduced |
| Wellington Management Group LLP | 33,801,113 | $3.50B | 0.60% | +11,233,381+49.8% | Added |
| Geode Capital Management, LLC | 29,899,653 | $3.08B | 0.16% | +440,611+1.5% | Added |
| FMR LLC | 28,920,617 | $2.99B | 0.13% | −2,276,273−7.3% | Reduced |
| Vanguard Portfolio Management LLC | 26,637,259 | $2.76B | 0.12% | +639,911+2.5% | Added |
| Capital Research Global Investors | 24,329,151 | $2.52B | 0.35% | +4,316,819+21.6% | Added |